ABUS

Arbutus Biopharma Corporation - Common Stock (ABUS)

About Arbutus Biopharma Corporation - Common Stock (ABUS)

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Details

Daily high

$4.06

Daily low

$3.62

Price at open

$4.02

52 Week High

$5.45

52 Week Low

$3.50

Market cap

804.3M

Dividend yield

Volume

41,613

Avg. volume

2.5M

P/E ratio

5.18

Arbutus Biopharma Corporation - Common Stock News